"Breakthrough Drug Combo Enhances Advanced Prostate Cancer Survival by 40%"

A new drug combination has been shown to reduce the risk of death from advanced prostate cancer by 40%, significantly improving survival rates for patients.

• The trial demonstrated that the drug combination can extend the lives of men with advanced prostate cancer by approximately 15 years for a 70-year-old patient.
• Study author Stephen Freedland, MD, from Cedars-Sinai Medical Center, highlighted that this breakthrough could transform treatment outcomes for men whose cancer has recurred.
• Results from the trial, reported on October 21, 2025, mark a significant advancement in how advanced prostate cancer is treated, offering hope to many patients.